Probity Advisors Inc. trimmed its holdings in shares of Aetna Inc. (NYSE:AET) by 3.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,189 shares of the company’s stock after selling 330 shares during the period. Probity Advisors Inc.’s holdings in Aetna were worth $1,620,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of the business. Guardian Life Insurance Co. of America raised its holdings in shares of Aetna by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 1,353 shares of the company’s stock worth $173,000 after purchasing an additional 9 shares during the period. Financial Architects Inc raised its holdings in shares of Aetna by 1.8% during the second quarter. Financial Architects Inc now owns 1,746 shares of the company’s stock worth $265,000 after purchasing an additional 31 shares during the period. Wedbush Securities Inc. raised its holdings in shares of Aetna by 1.4% during the second quarter. Wedbush Securities Inc. now owns 3,779 shares of the company’s stock worth $574,000 after purchasing an additional 52 shares during the period. Calamos Wealth Management LLC raised its holdings in shares of Aetna by 0.7% during the second quarter. Calamos Wealth Management LLC now owns 8,919 shares of the company’s stock worth $1,354,000 after purchasing an additional 65 shares during the period. Finally, HM Payson & Co. raised its holdings in shares of Aetna by 0.5% during the first quarter. HM Payson & Co. now owns 12,861 shares of the company’s stock worth $1,641,000 after purchasing an additional 69 shares during the period. 89.45% of the stock is currently owned by institutional investors.
In other news, EVP Margaret M. Mccarthy sold 10,288 shares of the business’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $162.85, for a total transaction of $1,675,400.80. Following the completion of the transaction, the executive vice president now directly owns 33,563 shares in the company, valued at approximately $5,465,734.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, President Karen S. Lynch sold 15,271 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $161.91, for a total value of $2,472,527.61. Following the transaction, the president now owns 64,261 shares of the company’s stock, valued at $10,404,498.51. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.
Aetna Inc. (NYSE AET) traded down 0.67% during trading on Tuesday, reaching $170.08. 2,668,816 shares of the company’s stock traded hands. The company has a market capitalization of $56.48 billion, a price-to-earnings ratio of 37.75 and a beta of 0.53. The firm’s 50 day moving average is $159.56 and its 200-day moving average is $151.91. Aetna Inc. has a 12 month low of $104.59 and a 12 month high of $184.98.
Aetna (NYSE:AET) last released its quarterly earnings results on Tuesday, October 31st. The company reported $2.45 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.07 by $0.38. The business had revenue of $14.99 billion during the quarter, compared to analysts’ expectations of $15.12 billion. Aetna had a return on equity of 20.52% and a net margin of 2.52%. The firm’s revenue for the quarter was down 5.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.07 earnings per share. Analysts expect that Aetna Inc. will post $9.49 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Shareholders of record on Thursday, October 12th were issued a dividend of $0.50 per share. The ex-dividend date was Wednesday, October 11th. This represents a $2.00 annualized dividend and a yield of 1.17%. Aetna’s dividend payout ratio is currently 43.67%.
AET has been the topic of a number of research reports. Zacks Investment Research raised shares of Aetna from a “hold” rating to a “buy” rating and set a $174.00 target price on the stock in a report on Thursday, October 12th. Jefferies Group LLC reissued a “hold” rating and set a $163.00 target price (up from $157.00) on shares of Aetna in a report on Friday, August 4th. Deutsche Bank AG increased their target price on shares of Aetna from $157.00 to $163.00 and gave the stock a “hold” rating in a report on Monday, August 7th. Credit Suisse Group reissued an “outperform” rating and set a $165.00 target price (up from $160.00) on shares of Aetna in a report on Thursday, July 13th. Finally, BMO Capital Markets initiated coverage on shares of Aetna in a report on Monday, October 16th. They set a “market perform” rating and a $175.00 target price on the stock. Nine research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $163.67.
Aetna Company Profile
Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.
Want to see what other hedge funds are holding AET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aetna Inc. (NYSE:AET).
What are top analysts saying about Aetna Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aetna Inc. and related companies.